This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Orvepitant

NeRRe Therapeutics, Ltd.

Drug Names(s): GW823296

Description: Orvepitant is a neurokinin 1 (NK1) antagonist.

Deal Structure: NeRRe and GSK
In December 2012, NeRRe Therapeutics has been launched to develop a portfolio of clinical and preclinical neurokinin receptor antagonists divested from GlaxoSmithKline (GSK).


Orvepitant News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug